EUVIMEDEUVIMED entdecken
Crossref

Effect Of Long-Term Use Of Antithrombotics And Statins On COVID-19 Mortality And Clinical Severity

Emrah Aksakal, Selim Aydemir, Faruk Aydınyılmaz, Murat Özmen

Recent Trends in Pharmacology · 2024

DOI: 10.62425/rtpharma.1534162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Recent Trends in Pharmacology, 2024. Verfasst von Emrah Aksakal und 3 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Gefördert von: None.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Coronavirus Disease-2019 (COVID-19), has affected the whole world and is still an important disease with its mutations. In our study, we aimed to evaluate the effects of antithrombotic agents [acetylsalicylic acid (ASA), P2Y12 inhibitors, oral anticoagulants (OACs)] and statin treatments used before hospitalization on COVID-19 mortality and clinical severity.

Methods

A retrospective study was conducted on 5577 patients hospitalized with positive swab tests or findings consistent with COVID-19 on computed tomography. The 6-month mortality, in-hospital mortality, need for intensive care and intubation, and recurrent hospitalization outcomes of patients receiving chronic ASA (n=1210), P2Y12 inhibitors (n=357), OACs (n=1192), and statin (n=607) treatment were evaluated.

Results

The 6-month mortality rate was 13.5% (n=754), in-hospital mortality rate was 11.2% (n=627), the rate of admission to the intensive care unit was 16.1% (n=897), the need for intubation was 8.8% (n=493), and the rate of recurrent hospitalization was 10.4% (n=579). ASA and OACs reduced all outcomes. P2Y12 inhibitors provided benefit in other endpoints except intubation. Statins used before hospitalization did not provide a statistically significant decrease in 6-month mortality (p: 0.06), but were associated with a decrease in the rates of in-hospital mortality, need for intensive care, recurrent hospitalization, and intubation.

Conclusion

We found that long-term ASA, P2Y12 inhibitors, OACs and statin treatments used before hospitalization in patients hospitalized with COVID-19, reduced COVID-19 mortality and clinical severity. We think that these treatments may be beneficial in selected patient groups where post-COVID effects are observed.

Förderung

  • None

Zitieren

APA

Aksakal, E., Aydemir, S., Aydınyılmaz, F., & Özmen, M. (2024). Effect Of Long-Term Use Of Antithrombotics And Statins On COVID-19 Mortality And Clinical Severity. Recent Trends in Pharmacology. https://doi.org/10.62425/rtpharma.1534162

Vancouver

Aksakal E, Aydemir S, Aydınyılmaz F, Özmen M. Effect Of Long-Term Use Of Antithrombotics And Statins On COVID-19 Mortality And Clinical Severity. Recent Trends in Pharmacology. 2024. doi:10.62425/rtpharma.1534162

BibTeX
@article{Aksakal2024,
  author = {Aksakal, Emrah and Aydemir, Selim and Aydınyılmaz, Faruk and Özmen, Murat},
  title = {Effect Of Long-Term Use Of Antithrombotics And Statins On COVID-19 Mortality And Clinical Severity},
  journal = {Recent Trends in Pharmacology},
  year = {2024},
  doi = {10.62425/rtpharma.1534162}
}
Kostenlos starten →